# Goodpasture Syndrome

Treat suspected Goodpasture syndrome as a pulmonary-renal emergency: stabilize hypoxemia and kidney failure, obtain anti-GBM and ANCA serologies urgently, pursue kidney biopsy when feasible, and initiate antibody removal plus immunosuppression promptly when clinical probability is high.

**Clinical question:** How should physicians rapidly diagnose, stabilize, and treat suspected Goodpasture syndrome with pulmonary hemorrhage and rapidly progressive glomerulonephritis?

Updated: 2026-08-24T18:19:05.548090+00:00

## What matters in practice
- In a patient with diffuse alveolar hemorrhage plus active glomerulonephritis or rapidly worsening kidney function, send anti-GBM antibodies and ANCA concurrently and involve nephrology urgently; anti-GBM disease is a life-threatening cause of pulmonary-renal syndrome. [1][12][14]
- A positive anti-GBM assay in the compatible clinical setting supports the diagnosis, but kidney biopsy establishes the characteristic pattern of necrotizing/crescentic glomerulonephritis with linear IgG along glomerular basement membranes and remains important when serology is negative or the presentation is atypical. [7][9][12][22]
- Prompt plasma exchange combined with glucocorticoids and cyclophosphamide is the established induction approach; delay risks irreversible kidney injury, while pulmonary hemorrhage is often treatment-responsive. [12][18][19]
- Test for concomitant ANCA because dual positivity occurs in 30% to 40% of patients and changes follow-up: relapse is uncommon in isolated anti-GBM disease but maintenance immunosuppression is recommended with concomitant ANCA. [12]
- At presentation requiring renal replacement therapy, renal recovery is less favorable; among patients not requiring renal replacement therapy initially, more than 80% maintain independent renal function at 1 year with aggressive treatment. [12]

## Treat pulmonary-renal syndrome as an emergency

Stabilization and diagnostic sampling should proceed in parallel.

Admit patients with suspected diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis to a monitored setting; transfer to intensive care when hypoxemia, respiratory failure, or hemodynamic instability is present. Intubate for respiratory failure and initiate urgent hemodialysis for standard indications rather than waiting for diagnostic confirmation. [18]

The key actionable syndrome is pulmonary hemorrhage with glomerulonephritis: Goodpasture syndrome denotes anti-GBM disease with hemorrhagic pneumonitis, whereas anti-GBM disease can be renal-limited. Rapid loss of kidney function with active urinary abnormalities and diffuse pulmonary infiltrates should trigger an immediate anti-GBM-centered workup. [1][4][7][23]

Do not use hemoptysis alone to exclude alveolar hemorrhage. Pulmonary hemorrhage may be clinically apparent or detected by imaging, pulmonary function testing, or bronchoscopy; evaluate the pulmonary process while simultaneously documenting kidney involvement with serum creatinine and urinalysis. [12]
- Send anti-GBM antibody testing immediately when pulmonary-renal syndrome or crescentic rapidly progressive glomerulonephritis is suspected. [12][18]
- Send ANCA concurrently; dual anti-GBM/ANCA disease is clinically important for relapse risk and maintenance therapy. [7][12][14]
- Obtain a kidney biopsy as soon as the patient's clinical condition permits; do not defer biopsy merely because anti-GBM serology is pending. [9][18]

*Immediate decisions in suspected Goodpasture syndrome. [12][18]*

| Clinical problem | Immediate action | Decision consequence |
| --- | --- | --- |
| Respiratory failure from suspected alveolar hemorrhage | Escalate to critical care and intubate when respiratory failure is present. [18] | Provides ventilatory support while antibody-directed therapy is initiated. [18] |
| Severe kidney failure | Start urgent hemodialysis for standard indications. [18] | Renal replacement therapy supports the patient but signals a less favorable renal prognosis. [12][18] |
| Pulmonary-renal syndrome or rapidly progressive GN | Order anti-GBM antibodies and ANCA; arrange kidney biopsy when feasible. [7][12][18] | Separates anti-GBM disease from ANCA-associated vasculitis and establishes tissue diagnosis when needed. [7][12] |

## Confirm anti-GBM disease and identify overlap syndromes

Interpret serology with the renal and pulmonary phenotype rather than in isolation.

Anti-GBM disease is mediated by autoantibodies directed predominantly against the noncollagenous domain of the alpha-3 chain of type IV collagen in glomerular and alveolar basement membranes. The clinically decisive consequence is capillaritis presenting as rapidly progressive glomerulonephritis, pulmonary hemorrhage, or both. [1][10][12][18]

Use a circulating anti-GBM antibody assay as the rapid diagnostic test in a compatible syndrome. Meta-analytic data cited in a recent case report estimate 93% sensitivity and 97% specificity for anti-GBM antibody detection; approximately 90% of affected patients have serum antibodies detectable by ELISA. A negative assay therefore lowers probability but does not exclude disease when the clinical trajectory and renal pathology are compelling. [9][22]

Kidney biopsy is the key adjudicating test when diagnosis is uncertain, antibodies are negative, or an atypical course suggests an alternative process. The defining immunofluorescence finding is continuous linear IgG staining along glomerular basement membranes, usually accompanied by diffuse necrotizing and crescentic glomerulonephritis. Crescent formation is reported in 95% of biopsy series, and more than 50% of glomeruli are affected in approximately 80% of cases. [7][22][24]

Interpret ANCA positivity as an overlap phenotype rather than a reason to dismiss anti-GBM disease. ANCA is present in 30% to 40% of anti-GBM cases; because isolated anti-GBM disease rarely relapses but ANCA-associated disease does, dual-positive patients require a maintenance-immunosuppression plan after induction. [12]
- Renal-limited anti-GBM disease: glomerulonephritis without pulmonary hemorrhage; up to half of affected patients may have kidney involvement alone. [24]
- Goodpasture syndrome: anti-GBM disease with pulmonary hemorrhage and glomerulonephritis. [4][10][24]
- Pulmonary-limited anti-GBM disease: rare; consider when hemorrhage is otherwise unexplained, particularly if conventional assays are negative but clinical suspicion persists. [12][24]

### Pulmonary-renal differential that changes testing and treatment

The highest-priority competing diagnosis is ANCA-associated vasculitis, because it can also produce rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage, and it may coexist with anti-GBM antibodies. Systemic lupus erythematosus and IgA nephritis are also reported associations with anti-GBM vasculitis; obtain ANCA and other disease-directed serologies when the renal or systemic phenotype suggests an immune-complex or vasculitic alternative. [3][6][14]

Use biopsy immunofluorescence to distinguish linear anti-GBM deposition from other glomerular patterns. Linear IgG along the GBM supports anti-GBM disease; if serology and pathology conflict, retain a broad differential because atypical anti-GBM presentations and rare antibody-negative cases occur. [9][22][24]

*Diagnostic patterns in anti-GBM disease and major pulmonary-renal alternatives. [3][6][7][12][22]*

| Pattern | Tests that discriminate | Interpretation and next step |
| --- | --- | --- |
| Anti-GBM disease | Serum anti-GBM antibody; kidney biopsy with direct immunofluorescence. [7][22] | Compatible serology plus GN supports diagnosis; linear GBM IgG with necrotizing/crescentic GN confirms the characteristic renal lesion. [7][12][22] |
| ANCA-associated vasculitis | ANCA testing with kidney biopsy. [3][7][14] | ANCA may identify AAV or anti-GBM/AAV overlap; dual-positive disease requires maintenance immunosuppression after induction. [12] |
| Immune-complex or associated systemic disease | Disease-directed serologies and kidney biopsy. [6][14] | Consider lupus or IgA nephritis when clinical or pathologic features are not typical of isolated anti-GBM disease. [6] |
| Seronegative or atypical anti-GBM disease | Kidney biopsy despite negative conventional anti-GBM assay. [9][24] | Linear IgG deposition can establish anti-GBM disease when circulating antibodies are not detected. [9][24] |

## Start antibody removal and immunosuppression promptly

Induction targets circulating pathogenic antibody, antibody production, and inflammatory organ injury.

For suspected anti-GBM disease with rapidly progressive glomerulonephritis and/or pulmonary hemorrhage, initiate plasma exchange with glucocorticoids and cyclophosphamide promptly in coordination with nephrology. This combination is the established treatment approach: plasma exchange removes pathogenic circulating anti-GBM antibodies, cyclophosphamide suppresses ongoing antibody production, and glucocorticoids suppress end-organ inflammation. [12][15][18][19]

Do not delay treatment solely for biopsy confirmation when the clinical probability is high and organ injury is progressing. Serologic results may take several days, while early diagnosis and treatment are emphasized to prevent irreversible renal failure and life-threatening pulmonary complications. Obtain renal tissue as soon as the patient can safely undergo biopsy. [9][18]

Plasma exchange is central for anti-GBM disease, unlike ANCA-associated vasculitis where recommendations are more selective. In AAV, plasma exchange may be considered for rapidly progressive glomerulonephritis with serum creatinine at least 5.7 mg/dL or severe diffuse alveolar hemorrhage; this threshold is an AAV recommendation and should not be substituted for the anti-GBM treatment strategy. [3][12]

Use hemodialysis as supportive renal replacement for standard indications, not as a substitute for disease-directed induction. Renal prognosis is strongly linked to severity at presentation: independent renal function at 1 year is maintained in more than 80% of aggressively treated patients who did not require renal replacement therapy initially. [12][18]
- Plasma exchange: remove circulating pathogenic antibody as part of induction. [12][18][19]
- Glucocorticoids: suppress inflammatory organ injury as part of induction. [12][15]
- Cyclophosphamide: suppress ongoing anti-GBM antibody production as part of induction. [12][15]
- Mechanical ventilation and hemodialysis: provide organ support when respiratory failure or standard dialysis indications are present. [18]

### Treatment goals differ by organ presentation

Pulmonary hemorrhage is generally responsive to plasma exchange plus cyclophosphamide and corticosteroids, and long-term respiratory sequelae are uncommon. The immediate objective is to reverse hemorrhage and hypoxemia while preventing recurrent injury. [12]

Renal recovery is less predictable than pulmonary recovery. A patient already requiring renal replacement therapy at presentation has a worse renal outlook than one treated before dialysis is necessary, which reinforces the urgency of treatment and biopsy early in the course. [12][18]

*Induction strategy by clinical presentation. [12][18]*

| Presentation | Disease-directed treatment | Supportive intervention |
| --- | --- | --- |
| Rapidly progressive GN with positive or strongly suspected anti-GBM disease | Prompt plasma exchange plus glucocorticoids and cyclophosphamide. [12][18] | Hemodialysis for standard indications. [18] |
| Diffuse alveolar hemorrhage with anti-GBM disease | Prompt plasma exchange plus glucocorticoids and cyclophosphamide. [12] | Critical care escalation and intubation for respiratory failure. [18] |
| Anti-GBM/ANCA dual positivity | Induction as anti-GBM disease with plasma exchange, glucocorticoids, and cyclophosphamide. [12] | Plan maintenance immunosuppression after induction because relapse risk follows the ANCA-associated component. [12] |

## Monitor renal trajectory, pulmonary response, and ANCA-associated relapse risk

Follow-up intensity should reflect whether disease is isolated anti-GBM or dual-positive.

Monitor clinical pulmonary status, oxygen requirement, serum creatinine, and urinary findings during induction to determine whether hemorrhage and glomerular injury are responding. Anti-GBM titers can fall rapidly with plasma exchange, but treatment response must be judged against organ-level improvement because kidney injury may already be irreversible. [2][12]

For isolated anti-GBM disease, relapse is uncommon after effective induction. In contrast, dual anti-GBM/ANCA positivity requires maintenance immunosuppression because the ANCA-associated component confers relapse risk; ensure ANCA results are reviewed before finalizing the post-induction plan. [12]

Counsel patients to eliminate exposures linked to disease onset, particularly tobacco and hydrocarbon solvents. Smoking and hydrocarbon exposure are reported environmental precipitants in genetically susceptible individuals and are particularly relevant in a syndrome involving alveolar-capillary injury. [10][18]
- Reassess respiratory support needs and evidence of pulmonary hemorrhage during induction. [12][18]
- Trend kidney function and urinary abnormalities to define renal response and dialysis dependence. [7][12][18]
- Document anti-GBM and ANCA status before discharge planning; ANCA positivity changes the need for maintenance immunosuppression. [12]
- Address smoking and hydrocarbon-solvent exposure as modifiable potential precipitants. [10][18]

*Follow-up decisions after initial control of anti-GBM disease. [10][12][18]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Pulmonary hemorrhage improves | Pulmonary disease is commonly responsive to plasma exchange, cyclophosphamide, and corticosteroids. [12] | Continue organ-level reassessment while completing the induction strategy. [12] |
| Kidney function remains severely impaired or dialysis-dependent | Renal prognosis is more variable and is worse when renal replacement therapy was needed at presentation. [12][18] | Continue nephrology-directed renal replacement and assess recovery over time. [18] |
| Concomitant ANCA positivity | Relapse risk is higher than in isolated anti-GBM disease. [12] | Use maintenance immunosuppression after induction. [12] |
| Ongoing tobacco or hydrocarbon-solvent exposure | These exposures are associated with disease onset in susceptible individuals. [10][18] | Provide cessation and exposure-avoidance counseling. [10][18] |

## Common questions

### Can anti-GBM disease be diagnosed when the serum anti-GBM assay is negative?

Yes. Negative serology does not exclude anti-GBM disease in a high-probability pulmonary-renal presentation. Proceed to kidney biopsy when feasible; linear IgG deposition along the GBM with crescentic glomerulonephritis can establish the diagnosis in rare seronegative cases. [9][22][24]

## References
1. Anti-glomerular basement membrane (Goodpasture's) disease - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/479
2. Goodpasture syndrome: a rare case presenting with recurrent haemoptysis | BMJ Case Reports — casereports.bmj.com — https://casereports.bmj.com/content/17/1/e252666
3. EULAR/ERA-EDTA recommendations for the management ... — ard.bmj.com — https://ard.bmj.com/content/annrheumdis/early/2016/06/23/annrheumdis-2016-209133.full.pdf
4. Variant "Goodpasture's Syndrome"?: The Need for ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-75-1-67
5. Protein A immunoadsorption for anti-glomerular basement ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)11080-8
6. Anti-glomerular basement membrane vasculitis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1568997222001823
7. Goodpasture Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/goodpasture-syndrome
8. Chapter 11 Anti-GBM Disease: Mechanisms, Clinical Features, and Treatment - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1571507807070110
9. Antibody‐Negative Relapse of Goodpasture Syndrome with Pulmonary Hemorrhage - Rohm - 2019 - Case Reports in Medicine - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2019/2975131
10. Goodpasture Syndrome - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/goodpasture-syndrome
11. Kidney Lesions Associated with Systemic Vasculitis — journals.lww.com — https://journals.lww.com/sjkd/fulltext/2001/12040/kidney_lesions_associated_with_systemic.14.aspx
12. Antiglomerular Basement Membrane Disease : Seminars in Respiratory & Critical Care Medicine — journals.lww.com — https://journals.lww.com/00019574-201808000-00009
13. Update on antiglomerular basement membrane disease — journals.lww.com — https://journals.lww.com/co-rheumatology/fulltext/2011/01000/update_on_antiglomerular_basement_membrane_disease.7.aspx?Ppt=Article%7Cco-rheumatology%3A2011%3A01000%3A00007%7C10.1097%2Fbor.0b013e328341009f%7C
14. Simultaneous comprehensive multiplex autoantibody... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2016/11010/simultaneous_comprehensive_multiplex_autoantibody.35.aspx?Ppt=Article%7Cmd-journal%3A2016%3A11010%3A00035%7C10.1097%2Fmd.0000000000005225%7C
15. Plasma Exchange for Anti‐GBM Disease With Dialysis ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/1744-9987.70121
16. Guidelines on the Use of Therapeutic Apheresis in Clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jca.21705
17. The Japanese Society for Apheresis clinical practice ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1744-9987.13749
18. Goodpasture Syndrome - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459291
19. Immunoadsorption in Anti-GBM Glomerulonephritis: Case ... — publications.aap.org — https://publications.aap.org/pediatrics/article/140/5/e20161733/37848/Immunoadsorption-in-Anti-GBM-Glomerulonephritis
20. Nephritis | Pediatric Care Online — publications.aap.org — https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396199/1625/Nephritis
21. Index of Suspicion | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/31/11/477/33178/Index-of-Suspicion
22. Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10392201
23. An Unusual Case of Anti-GBM Antibody Elevation in HIV-Associated Nephropathy - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4065736
24. Atypical anti-glomerular basement membrane disease - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4792615

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.